PTO/SB/08a (01-09) Approved for use through 02/28/2009. OMB 0551-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

nder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) of

Application Number 10/580,962 Filing Date May 31, 2006 First Named Inventor Erik Buntinx Art Unit 4121 Sarah Pihonak **Examiner Name** 29248/29 Attorney Docket Number

			U. S. PATEN1	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
		Number-Kind Code <sup>2 (filmoun)</sup>			r igures Appeur
	1	USPTO Office Action dated 03/13/200 12/02/2003, Examiner Umamaheswar		J.S. Application Senal No. 10,725,965, filed Jnt 1617.	
	2	USPTO Office Action dated 09/15/200 12/02/2003, Examiner Umamaheswar			
	3	USPTO Office Action dated 03/08/200 05/31/2006, Examiner Sarah Pihonak,			
	4	USPTO Office Action dated 10/21/200 filed 11/09/2004, Examiner Anna Page			
	5	USPTO Office Action dated 02/20/200 03/18/2004, Examiner Benjamin J. Par			
	6	USPTO Office Action dated 09/02/2008 03/18/2004, Examiner Benjamin J. Pac			
	7	USPTO Office Action dated 02/19/200 01/06/2004, Examiner Umamaheswari			
	8	USPTO Office Action dated 05/13/200			
		01/06/2004, Examiner Umamaheswari			
	9	US- 6,150,353	11-21-2000	Broekkamp et al.	
	10	USPTO Office Action dated 06/20/200 01/06/2004, Examiner Umamaheswar		J.S. Application Serial No. 10/752,423 filed Unit 1617.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	75	
		Country Code <sup>3</sup> 'Number <sup>4</sup> 'Kind Code <sup>5</sup> (d' known)	WINI-DD-11111		Or Neisvent rigures Appeal	Ŀ	

Examiner Signature /Sarah Pihonak/	Date Considered	05/14/2009
------------------------------------	--------------------	------------

"EXAMNER, initial it reference considered, whether or not obtation is in conformance with MPEP 699. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicants valued citation designation number (optional). "See Kristo Scies of USPTO Patent Downmost at <u>www.uspo.gov</u> or MPEP 991.04." Either Office that issued the document, by the two-effect code (WPD Standard ST.3." For Japanese patent documents by a milk of the patent document with the properties symbols as indicated on the year of the rigin of the Emperer must proceed the senial number of the patent document. Kind of document by the appropriate symbols as indicated on the document down WPD Standard ST.18 if a possible. "Applicant is to place a check mark here I English integrage." Translation is attached.

This collection of information is required by 37 CFR 1,97 and 1,98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. including gethering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08a (01-09)

Approved for use through 02/28/2009. OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Application Number 10/580,962 Filing Date May 31, 2006 First Named Inventor Erik Buntinx Art Unit 4121 Sarah Pihonak **Examiner Name** Attorney Docket Number 29248/29

				DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (Finour)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
	11			J.S. Application Serial No. 10/803,793 filed	
	12	USPTO Office Action dated 05/14/20 11/09/2004, Examiner Carlic K. Huyr			
	13	US- 4,797,419	01-10-1989	Moos et al.	
		US-			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Oocument	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	7°	
	_				<del> </del>	t	
						Γ	
					<u> </u>	┡	
Evaminar	_			L Date 1		느	
Examiner Signature		/Sarah Pihonak/		Date Considered	05/14/2009		

"EXAMINER: Initial if interence considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered, include copy of this from with next communication to applicant. Applicant varieupe citation designation number (options). "See Kinds Codes of USPTO Patent Documents at <a href="https://www.patents.org/winds-patents-paten Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the This collection of information is required by 37 CPR 1.97 and 1.38. The information is required to obtain or return a benefit by the public which is to the (and by the USPTO by posses) an application. Confidentially is governed by 33 U.S. C. 12 and 37 CPR 1.14. This collection is estimated to last 2 Abrus 10 completel, including applienting, preparing, and submitting the completed application from to the USPTO. This will vary depending upon this individual case. Any comments on the amount of time you required to complete his biom andioting depending this burden, should be sent to the Critic of information Officer. U.S. Patient and Trademant Confidence. P.O. Box 1450, Abexandria, W. A 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commission for Patients, P.O. Box 1450, Abexandria, W. A 2213-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08b (02-09)
Approved for use through 03/31/2009, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

\*\*Complete if Known\*\* Substitute for form 1449/PTO Application Number 10/580,962 INFORMATION DISCLOSURE Filing Date May 31, 2006 STATEMENT BY APPLICANT First Named Inventor Erik Buntinx Art Unit 4121 (Use as many sheets as necessary) Examiner Name Sarah Pihonak Attorney Docket Number Sheet 29248/29 3 3 of

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	14	JANSSEN-CILAB B.V instructions for Dipiperon tablets 40 mg. and Dipiperon drops 40 mg/ml.				
	15	WIRZ-JUSTICE A et al., "Haloperidol Disrupts, Clozapine Reinstates the Circadian Rest-Activity Cycle in a Patient With Early-Onset Alzheimer Disease," Alzheimer Disease				
		and Associated Disorders, Vol. 14, No. 4, pp. 212-215, 2000.				
	16	DECISION TO GRANT A EUROPEAN PATENT PURSUANT TO ARTICLE 97(1) EPC, dated February 19, 2009 in connection with EP Patent Application				
		No. 04025035.9, 2 pages.				
	17	COMMUNICATION UNDER RULE 71(3) EPC, dated October 13, 2008, in connection with EP Patent Application No. 04025035.9, 95 pages.				
	18	MAREK G J et al., "Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders," Online publication: 13 September 2002				
		at http://www.acnp.org/citations/Npp091302378,Neuropsychopharmacology 28: 402-12, 2003.				
	19	"ATYPICAL ANTIPSYCHOTIC AGENTS: MEDICAID DRUG USE REVIEW CRITERIA FOR OUTPATIENT USE," cited in 09/15/2008 Office Action in U.S. Patent Application No. 10/725,965, pp. 1-14.				

Signature	/Saran Pinonak/	Considered	05/14/2009
*EYAMINED: I	tiel if reference considered whether or not citation is in conform	ones with MDED CDD. Drow lies through a	ton has expermedade of ton hi politation

Examiner

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Date

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicants unique challon designation number (optional). 2 Applicant is to place a check must here if English Inaquage Tresistation is statisticed.

This collection of information is required by 37 CFH 18.8. The information is required to obtain or retired a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S. C. 122 and 37 CFH 1.1. This collection is estimated to take 2 hours to complete, including a signature of the complete in application from the but SPTO. Time will very depending upon the individual case. Any comments on the amount of stime you require to complete the policition form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of stime you require to complete the policition from the but SPTO. Time will very depending upon the individual case. Any comments on the amount of stime you require to complete the policition made to agree the policy of t